Imatinib potentiates anti-tumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

Imatinib mesylate targets mutated KIT oncoproteins in gastrointestinal stromal tumor (GIST) and achieves a clinical response in 80% of patients. The mechanism is believed to depend predominantly on the inhibition of KIT-driven signals for tumor cell survival and proliferation. Using a mouse model of...

Descripción completa

Detalles Bibliográficos
Autores principales: Balachandran, Vinod P., Cavnar, Michael J., Zeng, Shan, Bamboat, Zubin M., Ocuin, Lee M., Obaid, Hebroon, Sorenson, Eric C., Popow, Rachel, Ariyan, Charlotte, Rossi, Ferdinand, Besmer, Peter, Guo, Tianhua, Antonescu, Cristina R., Taguchi, Takahiro, Yuan, Jianda, Wolchok, Jedd D., Allison, James P., DeMatteo, Ronald P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278279/
https://www.ncbi.nlm.nih.gov/pubmed/21873989
http://dx.doi.org/10.1038/nm.2438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278279/
https://www.ncbi.nlm.nih.gov/pubmed/21873989
http://dx.doi.org/10.1038/nm.2438

Ejemplares similares